Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia

被引：3

作者：

Mabed, Mohamed ^{[1
,2
]}

Elhefni, Ashraf M. ^{[1
,3
]}

Damnhouri, Ghazi ^{[4
]}

机构：

[1] Dr Soliman Fakeeh Hosp, Hematol Unit, Jeddah, Saudi Arabia

[2] Mansoura Univ, Fac Med, Ctr Oncol, Div Hematol Med Oncol, Mansoura, Egypt

[3] Zagazig Univ, Fac Med, Dept Internal Med, Hematol Med Oncol Unit, Zagazig, Egypt

[4] King Abdulaziz Univ, King Fahd Res Ctr, Jeddah 21413, Saudi Arabia

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 11期

关键词：

BONE-MARROW APLASIA; CHRONIC MYELOGENOUS LEUKEMIA; MESYLATE; CELLS; THERAPY; EXPANSION; GROWTH;

D O I：

10.3109/10428194.2012.680452

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2310 / 2311

页数：2

共 19 条

[1] Inhibitory effect of imatinib on normal progenitor cells in vitro [J].

Bartolovic, K ;

Balabanov, S ;

Hartmann, U ;

Komor, M ;

Boehmler, AM ;

Bühring, HJ ;

Möhle, R ;

Hoelzer, D ;

Kanz, L ;

Hofmann, WK ;

Brümmendorf, TH .

BLOOD, 2004, 103 (02) :523-529

[2] Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells [J].

Brummendorf, TH ;

Dragowska, W ;

Zijlmans, JMJM ;

Thornbury, G ;

Lansdorp, PM .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (06) :1117-1124

[3] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[4] Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors [J].

Dewar, AL ;

Domaschenz, RM ;

Doherty, KV ;

Hughes, TP ;

Lyons, AB .

LEUKEMIA, 2003, 17 (09) :1713-1721

[5] CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs [J].

Fang, GF ;

Kim, CN ;

Perkins, CL ;

Ramadevi, N ;

Winton, E ;

Wittmann, S ;

Bhalla, KN .

BLOOD, 2000, 96 (06) :2246-2253

[6] Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro [J].

Graham, SM ;

Jorgensen, HG ;

Allan, E ;

Pearson, C ;

Alcorn, MJ ;

Richmond, L ;

Holyoake, TL .

BLOOD, 2002, 99 (01) :319-325

[7] Indications for imatinib mesylate therapy and clinical management [J].

Guilhot, F .

ONCOLOGIST, 2004, 9 (03) :271-281

[8] Effects of imatinib on bone marrow engraftment in syngeneic mice [J].

Hoepfl, J ;

Miething, C ;

Grundler, R ;

Götze, KS ;

Peschel, C ;

Duyster, J .

LEUKEMIA, 2002, 16 (09) :1584-1588

[9] Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation [J].

Holtz, MS ;

Slovak, ML ;

Zhang, FY ;

Sawyers, CL ;

Forman, SJ ;

Bhatia, R .

BLOOD, 2002, 99 (10) :3792-3800

[10]

Khan KA, 2008, JCPSP-J COLL PHYSICI, V18, P176, DOI 03.2008/JCPSP.176178

← 1 2 →